Article
Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies.
Frontiers in immunology - 1 Jan 2021
Chasov Vitaly, Zaripov Mikhail, Mirgayazova Regina, Khadiullina Raniya, Zmievskaya Ekaterina, Ganeeva Irina, Valiullina Aigul, Rizvanov Albert, Bulatov Emil
Abstract excerpt
Transcription factor and oncosuppressor protein p53 is considered as one of the most promising molecular targets that remains a high-hanging fruit in cancer therapy. TP53 gene encoding the p53 protein is known to be the most frequently mutated gene in human cancers. The loss of transcriptional functions caused by mutations in p53 protein leads to deactivation of intrinsic tumor suppressive responses associated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.